Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto- and allogeneic mesenchymal stromal cells for Crohn-related anal fistulas
2022-003197-23Phase 3Active
- Sponsor
- Jagiellonian University Medical College
- Start
- Jan 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous adipose-derived mesenchymal stromal cells and allogeneic adipose-derived mesenchymal stromal cells in anal fistula, Crohn's disease-related rectocutaneous fistula (RCF) and Crohn's disease-related rectovaginal fistula (CD-RVF) (3 arms), sponsored by Jagiellonian University Medical College. Primary endpoints: Fistula healing at 3 months and Fistula healing at 6 months. Started Jan 2023; status: active.
02
Drugs
autologous adipose-derived mesenchymal stromal cellsallogeneic adipose-derived mesenchymal stromal cells
03
Conditions
anal fistulaCrohn's disease-related rectocutaneous fistula (RCF)Crohn's disease-related rectovaginal fistula (CD-RVF)
Beyond the preview
Go deeper on 2022-003197-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003197-23.